Louisiana Clinical and Translational Science Center

路易斯安那州临床和转化科学中心

• 批准号: 10513330
• 负责人: JOHN P. KIRWAN
• 金额: $ 400万
• 依托单位: LSU PENNINGTON BIOMEDICAL RESEARCH CTR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-15 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10513330
• 关键词: Academic Medical Centers; Address; Administrative Supplement; Advisory Committees; Applications Grants; Area; Award; Bioinformatics; Biomedical Research; Biometry; Black race; COVID testing; COVID-19; COVID-19 pandemic; COVID-19 patient; COVID-19 testing; COVID-19 vaccination; Cardiovascular Diseases; Center for Translational Science Activities; Chronic Disease; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communication; Communities; Diabetes Mellitus; Disease Management; Diverse Workforce; Education; Ensure; Federally Qualified Health Center; Funding; Generations; Goals; Grant; Growth; Health; Health Care Research; Health Sciences; Healthcare Systems; Hurricane; Infrastructure; Inosine Dialdehyde; Institution; Institutional Review Boards; Investments; Lead; Long COVID; Longterm Follow-up; Louisiana; Malignant Neoplasms; Mission; Modeling; NCI Scholars Program; Obesity; Outcome; Patients; Pediatric Hospitals; Persons; Positioning Attribute; Post-Acute Sequelae of SARS-CoV-2 Infection; Productivity; Professional Education; Provider; Public Health; Publications; RADx Underserved Populations; Research; Research Infrastructure; Research Personnel; Resources; Role; Rural; School Dentistry; Scientist; Services; Structure; System; Teacher Professional Development; Testing; Time; Training; Translational Research; Trust; Underrepresented Minority; Underserved Population; United States National Institutes of Health; Universities; Vaccination; Veterans; Work; base; cohort; community engagement; coronavirus disease; diversity and inclusion; experience; health disparity; health equity; health literacy; high risk population; improved; infrastructure development; investigator training; minority communities; mortality; multidisciplinary; operation; pandemic disease; precision medicine; precision nutrition; pressure; programs; recruit; response; safety net; skills; social health determinants; synergism; underserved community; virtual platform

Project Summary: Overall The Louisiana Clinical and Translational Science (LA CaTS) Center is a consortium of the major academic and biomedical research centers in the State of Louisiana. Pennington Biomedical Research Center is the lead institution and will continue to partner with Louisiana State University Health (LSUH)-New Orleans and Tulane University Health Sciences Center in this initiative. LSUH-Shreveport, LSU-A&M (Baton Rouge), Xavier University and Children's Hospital New Orleans, were early Research Partners in cycle 1. Southeast Louisiana Veterans Healthcare System, a newly opened University Medical Center in New Orleans ($1 billion State investment), Ochsner Health and the LSUH-NO School of Dentistry joined during cycle 2. The LA CaTS Center is growing a unified clinical translational science program for Louisiana based on the creation of synergistic programs and unparalleled collaboration from all the major academic and biomedical research institutions in the state. Since inception 9 years ago, the LA CaTS Center has: 1) successfully leveraged resources and expertise of multiple participating institutions to build a vibrant statewide research infrastructure; 2) developed highly synergistic and integrative collaborative programs; 3) implemented a systematic approach to clinical research across all institutions, that includes a new SMART IRB Reliance Model review; and 4) implemented a highly effective governance system based on an unprecedented level of trust between partners. LA CaTS is experiencing exponential growth in research productivity as assessed by key metrics including a three-fold increase in external grant awards, a more than two-fold increase in publications with authors acknowledging LA CaTS Center resources and services and over 600 researchers benefiting from and using our services. Notably, during a period that has been marked by unique and unprecedented challenges from COVID and then Hurricane Ida, LA CaTS has achieved, and in many cases exceeded, its stated objectives and projected milestones. Indeed, since the COVID pandemic hit Louisiana in March of 2020, LA CaTS has led multiple successful grant applications for Administrative Supplements and NOSI awards, notably to facilitate COVID testing and vaccinations in underserved Black communities through the RADx-UP program and most recently our partnership with the IDeA state ISCORE consortium on the national Long-COVID initiative - Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)/RECOVER trial. However, we fully recognize that our work has only just begun, as we collectively address disparities and improve the lives of our citizens. It is also apparent, that slowly, but surely, we are impacting public health one project at a time! With new services proposed and the additional resources that will be added, our Center is uniquely positioned to devote our activities and resources to our major theme for the next 5-year cycle that will “address health disparities and improve the health outcomes of the citizens we serve”.

项目摘要：总体 路易斯安那州临床和转化科学（LA CATS）中心是主要学术的联盟 路易斯安那州的生物医学研究中心。彭宁顿生物医学研究中心是领导者 机构，并将继续与路易斯安那州立大学卫生（LSUH） - 新奥尔良和图兰 该计划的大学健康科学中心。 LSUH-shreveport，LSU-A＆M（巴吞鲁日），Xavier 新奥尔良大学和儿童医院是第1周期的早期研究伙伴。路易斯安那州东南部 退伍军人医疗保健系统，新奥尔良新开设的大学医学中心（10亿美元） 投资），Ochsner Health和LSUH-NO牙科学校在第2周期加入。 是基于协同作用而发展为路易斯安那州的统一临床转化科学计划 来自所有主要学术和生物医学研究机构的计划和无与伦比的合作 状态。自9年前成立以来，洛杉矶猫中心拥有：1）成功利用资源和专业知识 多个参与机构，以建立充满活力的全州研究基础设施； 2）高度发展 协同和综合协作计划； 3）实施系统的临床研究方法 在所有机构中，包括新的智能IRB Reliance模型审查； 4）实施高度 基于合作伙伴之间前所未有的信任水平的有效治理体系。 La Cats是 由关键指标评估的研究生产率的指数增长，包括三倍 外部赠款奖的增加，出版物的出版物增加了两倍以上，作者承认洛杉矶 猫中心资源和服务以及600多名研究人员从我们的服务中受益和使用。尤其， 在一个以独特而前所未有的挑战为标志的时期，然后是飓风 洛杉矶猫的艾达（Ida）已经取得了成就，在许多情况下，其既定的目标和预计的里程碑。 的确，自从2020年3月的联盟大流行袭击路易斯安那州以来，洛杉矶猫队领导了多个成功的格兰特 行政补充剂和NOSI奖的申请，特别是为了促进共同测试和 通过RADX-UP计划，服务不足的黑人社区的疫苗接种，最近我们 与Idea State ISCore联盟的合作伙伴关系在国家长期长期倡议上 - 急性后遗症 SARS-COV-2感染（PASC）/恢复试验。但是，我们完全认识到我们的工作只有 当我们共同解决分销并改善公民的生活时，开始了。也很明显，慢慢地 但是可以肯定的是，我们一次正在影响公共卫生一个项目！提出了新的服务和其他 将添加的资源，我们的中心是独特的位置，可以将我们的活动和资源投入到我们的专业 接下来的5年周期的主题将“解决健康分布并改善健康状况 我们服务的公民”。